MRI-Guided TULSA Effective at Five Years for Localized Prostate Cancer
By Lori Solomon HealthDay Reporter
MONDAY, March 25, 2024 -- For the treatment of localized prostate cancer, in-bore, magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) results in favorable outcomes at five years, including durable oncologic control and functional preservation, according to a study presented at the annual meeting of the Society of Interventional Radiology, held from March 23 to 28 in Salt Lake City.
Steven Raman, M.D., from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues evaluated the safety, quality of life, and oncological outcomes at five-year follow-up among 115 men with localized, predominantly intermediate-risk prostate cancer who underwent a single in-bore, MRI-guided TULSA treatment.
The researchers report that median prostate-specific antigen (PSA) decreased from 6.3 to 0.26 ng/mL nadir at year 1, durable to 0.63 ng/mL at five years. Additionally, median prostate volume decreased 92 percent at year 1. Twenty-five men (21.7 percent) received salvage treatment at five years, all without unexpected complications (10 prostatectomy, 11 radiotherapy, three radiation plus androgen deprivation therapy, and one surgery plus radiation). Treatment failure was predicted by PSA at one year (odds ratio, 3.0) and multiparametric MRI (odds ratio, 12.0). Preventable errors identified in a failure analysis included patient selection, calcification size and location, targeting, or misalignment due to intraprocedural swelling/motion. The majority of men at five years recovered pad-free continence (92 percent) and preserved erections sufficient for penetration (87 percent). One in 10 men had grade 3 adverse events, with none experiencing a grade 4 event or rectal injury.
"The success of TULSA represents a revolution in whole-gland treatment for prostate cancer," Raman said in a statement. "We have more research to do, but if validated, TULSA has the potential to change the standard of care for thousands of men."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Mortality in Rheumatic Heart Disease Is High
FRIDAY, June 7, 2024 -- Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June...
Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...
Metabolic Impact on Offspring Similar for Frozen, Fresh Embryo Transfer
FRIDAY, June 7, 2024 -- For glucose and lipid profiles during early childhood, the impact of frozen embryo transfer (FET) is comparable to that of fresh embryo transfer, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.